Skip to main content
An official website of the United States government
Email

Funding Portfolio

DCTD supports research across the entire spectrum of areas related to diagnostic and therapeutic approaches to cancer. The graph below depicts the distribution of the $1.44 billion in fiscal year 2024 grant funding managed by DCTD across the Programs and Offices with grant portfolios (the Biometric Research Program does not manage grants). The Developmental Therapeutics Program (DTP) had the largest number of awarded grants, totaling $499 million, followed by the Cancer Imaging Program (CIP) at $336 million. 

The distribution of grants across the various programmatic areas is representative of DCTD’s commitment to empowering innovative and cross-functional research to improve diagnostic approaches and facilitate the discovery, development, and effective administration of new treatments for patients diagnosed with cancer.

Distribution of DCTD FY2024 Grant Funding Across Programs ($ in millions)

Pie chart capturing the distribution of DCTD FY2024 Grant Funding Across Programs in millions

DCTD grant funding for fiscal year 2024 across programs/offices (Cancer Diagnosis Program, CDP; Cancer Imaging Program, CIP; Cancer Therapy Evaluation Program, CTEP; Developmental Therapeutics Program, DTP; Radiation Research Program, RRP; Translational Research Program, TRP; Office of Cancer Clinical Proteomics Research, OCCPR; and the Office of Cancer Complementary and Alternative Medicine, OCCAM).

 

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Funding Portfolio was originally published by the National Cancer Institute.”

Email